CollPlant reports Q3 non-GAAP EPS (35c), consensus (13c)

Reports Q3 GAAP revenue $43,000 consensus $3.5M. “This quarter, we continued to steadily advance our programs with modest cash use,” said CollPlant’s CEO, Yehiel Tal. “We are advancing our regenerative breast implants program, and plan to initiate by the end of this year an animal study with commercial size implants. With AbbVie, we continue to make progress with the dermal filler candidate, and, in addition, we were pleased to announce earlier this month that a U.S. patent was granted related to our photocurable dermal filler product candidate. We plan to continue our momentum towards the completion of important upcoming milestones for which we are entitled to associated payments, that will support our continued robust cash position”.